Home / Pharmaceutical company intelligence
CCL Pharmaceuticals (Pvt.) Limited logo
Pharmaceutical company intelligence

CCL Pharmaceuticals (Pvt.) Limited

Private pharmaceutical manufacturer · Lahore · Pakistan

Lahore-headquartered pharmaceutical and healthcare company with manufacturing operations and a multi-country commercial presence.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗ LinkedIn ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date23 Jul 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Private pharmaceutical manufacturer
Address
65, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore, Pakistan
Phone
+92 42 111 225 678
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000052 CCL Pharmaceuticals (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000052 203 linked products · source seen 23 Sep 2026 View source ↗
DML 000891 39 linked products · source seen 23 Sep 2026 View source ↗
DSL 05-354-0077-068122D 14 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx256public portfolio records represented
REG196unique registrations represented
IDX249indexed MedInfoBase presentations
SRC7additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR231current validated price records
G99generic molecules in indexed catalogue
DF9dosage-form groups
TA12therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage90%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage90%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixCCL Pharmaceuticals (Pvt.) LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/ccl-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026Anti-infectives77 · 31%Hematology & thrombosis33 · 13%CNS & mental health32 · 13%Oncology & immunology29 · 12%Cardiovascular28 · 11%Vitamins, minerals & nutrition20 · 8%Gastrointestinal & hepatology15 · 6%Other therapeutic areas15 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioCCL Pharmaceuticals (Pvt.) LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/ccl-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026249presentationsTablet138 · 55%Injection44 · 18%Capsule25 · 10%Cream11 · 4%Syrup11 · 4%Suspension10 · 4%Other forms10 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionCCL Pharmaceuticals (Pvt.) LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/ccl-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026224comparable productsBelow peer median27 · 12%Near peer median73 · 33%Above peer median124 · 55%Company median price position+6.0%Lowest-price equivalents13Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsCCL Pharmaceuticals (Pvt.) LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/ccl-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,49 shared49% overlapGenome Pharmaceuticals (Pvt.) Ltd.45 shared45% overlapM/s. Genix Pharma (Pvt) Ltd.43 shared43% overlapPharmasol (Pvt) Ltd.43 shared43% overlapHIGH-Q Pharmaceuticals43 shared43% overlapBio-Labs(Pvt) Ltd41 shared41% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives77 products · 31%
Hematology & thrombosis33 products · 13%
CNS & mental health32 products · 13%
Oncology & immunology29 products · 12%
Cardiovascular28 products · 11%
Vitamins, minerals & nutrition20 products · 8%
Gastrointestinal & hepatology15 products · 6%
Endocrine & metabolic7 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antineoplastic medicines24 products · 10%
Antiepileptics22 products · 9%
Vitamins / minerals / hematinics20 products · 8%
Anticoagulants17 products · 7%
Third-generation cephalosporins15 products · 6%
Antifungals14 products · 6%
Antivirals13 products · 5%
Antiplatelet medicines10 products · 4%
Formulation footprint

Dosage forms

Tablet138 products
Injection44 products
Capsule25 products
Cream11 products
Syrup11 products
Suspension10 products
Infusion5 products
Lotion3 products
Other2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 EPICETAMLevetiracetam 11presentations 1000 mg, 250 mg, 500 mg, 500 mg/5 mL · Tablet, Injection #2 XALIARivaroxaban 10presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #3 CEF-ODCefixime 5presentations 100 mg/5 mL, 200 mg, 400 mg · Suspension, Tablet, Capsule #4 DASIROXDeferasirox 5presentations 100 mg, 250 mg, 400 mg, 500 mg · Tablet #5 LEUCOFOLATECalcium folinate (folinic acid) 5presentations 100 mg, 15 mg, 50 mg · Injection #6 TACGRAFTacrolimus 5presentations 0.5 mg, 1 mg, 5 mg · Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2712% of comparable products
Near market median73within ±5% of median
Above market median12455% of comparable products
Lowest-price equivalents13ties included
Company median price position +6.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
TEGREY 100 mg/5 mLCarbamazepine · Suspension · 120ml PKR 0.81/mL-54.4% vs market median METOMIDE 10 mgMetoclopramide · Tablet · 20's PKR 1.04/tablet-53.9% vs market median Leukozole 150 mgFluconazole · Capsule · 1's PKR 135.06/capsule-48.8% vs market median Leukozole 150 mgFluconazole · Capsule · 2's PKR 135.06/capsule-48.8% vs market median STIVANT 400 mg/16 mLBevacizumab · Concentrate for solution for infusion · 1's PKR 102,238.25/vial/unit-44.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 49shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 45shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 43shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 43shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 43shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 41shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers191Distinct registrations among indexed, published, presentation-validated products only
Verified price observations249
Products with a verified price249
Products with multiple price observations0
Source records with multiple versions249
Latest portfolio source check22 Sep 2026
Latest effective price date23 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

196 unique registration(s) · 249 indexed presentation(s) · 7 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Spirodyn Spironolactone 100 mg Tablet 10's 113707 PKR 145.93 PKR 14.59/tablet 18% above median
Spirodyn Spironolactone 25 mg Tablet 100's 113710 PKR 307.49 PKR 3.07/tablet 33% below median
STIVANT Bevacizumab 100 mg Injection 1's 107905 PKR 25,715.63 PKR 25,715.63/vial/unit No comparator
STIVANT Bevacizumab 400 mg/16 mL Concentrate for solution for infusion 1's 107906 PKR 102,238.25 PKR 102,238.25/vial/unit 45% below median
SUCROFER-F Elemental iron + Folic acid 20 mg + 2.5 mg Tablet 14's 052640 PKR 336.18 PKR 24.01/tablet No comparator
SUCROFER-F Iron protein succinylate + Folic acid 800 mg iron protein succinylate (equiv. 40 mg elemental iron) + 5 mg folic acid/15 mL Syrup 120ml 057525 PKR 388.69 PKR 3.24/mL No comparator
SUCROFER-F Iron + Folic acid 800 mg/15 mL + 5 mg/15 mL Syrup 60ml 057525 PKR 203.79 PKR 3.40/mL No comparator
SUCROFER-S Iron protein succinylate 800 mg/15 mL (equiv. 40 mg elemental iron) Syrup 120ml 044605 PKR 378.20 PKR 3.15/mL 6% above median
SUCROFER-S Iron protein succinylate 800 mg/5 mL Syrup 60ml 044605 PKR 199.61 PKR 3.33/mL 7% above median
SUCROFER-T Iron protein succinylate 400 mg + 20 mg Tablet 14's 057526 PKR 315.16 PKR 22.51/tablet No comparator
TACAVIR Entecavir 0.5 mg Tablet 30's 055321 PKR 21,357.15 PKR 711.91/tablet 100% above median
TACAVIR Entecavir 1 mg Tablet 30's 055322 PKR 35,595.25 PKR 1,186.51/tablet 105% above median
TACAVIR Entecavir 0.05 mg/mL Oral suspension 210ml 062779 PKR 9,526.97 PKR 45.37/mL No comparator
TACGRAF Tacrolimus 0.5 mg Capsule 30's 068114 PKR 2,042.09 PKR 68.07/capsule 19% above median
TACGRAF Tacrolimus 0.5 mg Capsule 10's 068114 PKR 739.77 PKR 73.98/capsule 30% above median
TACGRAF Tacrolimus 1 mg Capsule 30's 068115 PKR 3,402.90 PKR 113.43/capsule 16% above median
TACGRAF Tacrolimus 1 mg Capsule 10's 068115 PKR 1,232.94 PKR 123.29/capsule 27% above median
TACGRAF Tacrolimus 5 mg Capsule 10's 068116 PKR 6,164.69 PKR 616.47/capsule 21% above median
TALAM Telmisartan + Amlodipine 5 mg + 40 mg Tablet 14's 093510 PKR 683.83 PKR 48.85/tablet Near median
TALAM Telmisartan + Amlodipine 10 mg + 40 mg Tablet 14's 093511 PKR 753.21 PKR 53.80/tablet Near median
TALAM Telmisartan + Amlodipine 80 mg + 10 mg Tablet 10's 097391 PKR 658.35 PKR 65.84/tablet 22% below median
TALAM Telmisartan + Amlodipine 10 mg + 80 mg Tablet 14's 097391 PKR 923.29 PKR 65.95/tablet 20% below median
TALAM Telmisartan + Amlodipine 5 mg + 80 mg Tablet 14's 097392 PKR 971.46 PKR 69.39/tablet 11% above median
TALAM 10/40 Amlodipine 10 mg Tablet 10's 093511 PKR 537.15 PKR 53.72/tablet 216% above median
TALAM 5/80 Telmisartan + Amlodipine 5 mg + 80 mg Tablet 10's 097392 PKR 529.89 PKR 52.99/tablet 17% below median
TEGREY Carbamazepine 100 mg/5 mL Suspension 120ml 045956 PKR 96.66 PKR 0.81/mL 54% below median
TELSARTAN PLUS Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 28's 093973 PKR 1,167.47 PKR 41.70/tablet Near median
TELSARTAN PLUS Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 14's 093973 PKR 614.45 PKR 43.89/tablet Near median
TENOVIR Tenofovir disoproxil 300 mg Tablet 30's 065743 PKR 7,125.30 PKR 237.51/tablet 6% above median
TENSORETIC Lisinopril 20 mg Tablet 10's 023849 PKR 428.11 PKR 42.81/tablet 44% above median
TOXIPLATIN Carboplatin 150 mg Injection Per vial 044851 PKR 4,595.30 PKR 4,595.30/vial/unit 6% above median
TOXIPLATIN Carboplatin 450 mg Injection Per vial 044852 PKR 9,190.61 PKR 9,190.61/vial/unit 8% above median
UROPHOS Calcium acetate 667 mg Tablet 30's 093764 PKR 178.39 PKR 5.95/tablet 19% above median
UROPHOS Calcium acetate 667 mg Tablet 100's 093764 PKR 496.39 PKR 4.96/tablet Near median
VONAL Voriconazole 200 mg Tablet 10's 097644 PKR 1,766.30 PKR 176.63/tablet 15% below median
XALIA Rivaroxaban 15 mg Tablet 14's 087491 PKR 9,871.52 PKR 705.11/tablet Near median
XALIA Rivaroxaban 15 mg Tablet 10's 087491 PKR 7,051.08 PKR 705.11/tablet Near median
XALIA Rivaroxaban 20 mg Tablet 14's 087492 PKR 12,496.07 PKR 892.58/tablet Near median
XALIA Rivaroxaban 20 mg Tablet 10's 087492 PKR 8,925.76 PKR 892.58/tablet Near median
XALIA Rivaroxaban 10 mg Tablet 14's 088484 PKR 7,892.47 PKR 563.75/tablet Near median
XALIA Rivaroxaban 10 mg Tablet 10's 088484 PKR 5,522.61 PKR 552.26/tablet Near median
XALIA Rivaroxaban 2.5 mg Tablet 28's 097641 PKR 5,398.51 PKR 192.80/tablet Near median
XALIA Rivaroxaban 2.5 mg Tablet 10's 097641 PKR 1,928.04 PKR 192.80/tablet Near median
XALIA Rivaroxaban 2.5 mg Tablet 14's 097641 PKR 2,839.86 PKR 202.85/tablet Near median
XALIA Rivaroxaban 2.5 mg Tablet 20's 097641 PKR 3,856.07 PKR 192.80/tablet Near median
XALIA 2.5 Rivaroxaban 2.5 mg Tablet 7's 097641 PKR 1,349.62 PKR 192.80/tablet Near median
XALIA 2.5 Rivaroxaban 2.5 mg Tablet 30's 097641 PKR 5,784.12 PKR 192.80/tablet Near median
XALIA 2.5 Rivaroxaban 2.5 mg Tablet 5's 097641 PKR 964.02 PKR 192.80/tablet Near median
XALIPLATIN Oxaliplatin 50 mg Injection Per vial 044848 PKR 20,215.87 PKR 20,215.87/vial/unit 13% above median
XALIPLATIN Oxaliplatin 100 mg Injection Per vial 044849 PKR 40,431.74 PKR 40,431.74/vial/unit 13% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). CCL Pharmaceuticals (Pvt.) Limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/ccl-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.